Edwards Lifesciences Corp
F:EWL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Edwards Lifesciences Corp (EWL) under the Base Case is 72.94 EUR per share.
Compared with the current market price of 92.74 EUR, the stock appears
Overvalued by 21% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Edwards Lifesciences Does
Edwards Lifesciences makes medical devices for people with serious heart disease. Its main products are replacement heart valves, including minimally invasive valves that can be delivered through a catheter instead of open-heart surgery, plus monitoring tools used in intensive care and during surgery. The company focuses on conditions where the heart cannot pump or valve properly, so its products help doctors treat patients with structural heart disease and monitor them closely in the hospital.
- Headquarters
- United States of America US
- Employees
- 16 000
- IPO date
- Mar 27, 2000
Edwards Lifesciences has a narrow economic moat
Protected valve technology, demanding approval requirements and the time doctors spend learning Edwards’ devices make it difficult for rivals to win business on price alone. These barriers provide lasting protection, although established competitors such as Medtronic and Abbott offer alternatives.
Read the full moat analysisBalance Sheet
Recent Events
Latest Earnings Call
Broad-based third-quarter strength led Edwards to raise its full-year outlook, while management emphasized widening TAVR access and developing new treatment opportunities.
What management delivered: 2 better than forecast
Open the earnings call- EPS
- $0.80
- Expected
- $0.73
- Surprise
- +9.6%
- Stock, next trading day
- +1.5%
Edwards Lifesciences insiders are selling within their usual range
Past 12 months
Continue EWL Research
Decided on Edwards Lifesciences? Get an email when EWL reaches the price you’d buy at. Free with an account.
Other Edwards Lifesciences listings
What is the Intrinsic Value of one EWL stock?
The intrinsic value for
Edwards Lifesciences Corp (EWL) under the Base Case is 72.94 EUR.
Is EWL stock undervalued or overvalued?
Compared with the current market price of 92.74 EUR, the stock appears Overvalued by 21% .